Lexaria Bioscience (CSE: LXX-OTCQX: LXRP) CEO Chris Bunka joined Steve Darling from Proactive with news the company has received ethics board approval to conduct a pilot human pharmacokinetic exploratory study of antiviral drugs that have previously been studied against other coronavirus strains, comparing Lexaria's DehydraTECH formulations to controls without Lexaria's technology.

Bunka telling Proactive how the study will work and also what the timing looks like as they have a few more steps to go through.